Clinical Trials
15 trialsNCT03600350 2026-06-01
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06254326 2026-05-27
ADAGiO
University of Florida
Phase 1 Recruiting
NCT00458536 2026-05-19
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT00629759 2026-05-19
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
SillaJen, Inc.
Phase 1 Completed
NCT07377435 2026-05-08
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Phase 1 Recruiting
NCT04936529 2026-05-07
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06799026 2026-05-07
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center
Phase 1 Recruiting
NCT07374029 2026-05-05
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
Beth Israel Deaconess Medical Center
Phase 1 Recruiting
NCT03334305 2026-04-23
ACTION
University of Florida
Phase 1 Terminated
NCT07537400 2026-04-17
Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5
Shaare Zedek Medical Center
Phase 2 Not yet recruiting
NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT04237623 2026-04-16
GM-CSF With Post-Transplant Cyclophosphamide
Northside Hospital, Inc.
Phase 2 Recruiting
NCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT06514898 2026-04-03
MATCHPOINT
University of Florida
Phase 1 Active not recruiting
NCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting